Price
38.9
-5.06%Market Cap
₹37.34 Cr
Traded: ₹0.33 Cr (0.88%) 0.0x
Free Float: ₹5.94 Cr (5.51% of FF traded)
Volume · 60D trend
84 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | +37.0% | -- | -- | -- |
| Sales | -- | -- | +17.0% | -- | +11.0% | Decelerating |
| Profit | -- | -- | +119.0% | -- | +42.0% | Decelerating |
| Return | -- | -- | -- | -- | -- | -- |
Quarterly Results
Sep 2025
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Sep 2025 | |
|---|---|---|
| Sales | 17 | 14 |
| Expenses | 13 | 11 |
| Operating Profit | 4 | 3 |
| OPM % | 24.9% | 19.0% |
| Other Income | 0 | 0 |
| Interest | 1 | 1 |
| Depreciation | 0 | 0 |
| Profit Before Tax | 4 | 2 |
| Tax % | 21.8% | 26.5% |
| Net Profit | 3 | 1 |
| Exceptional Items | -- | -- |
| EPS (Rs) | 4.0 | 2.0 |
| Sales Growth (YoY) | -- | -- |
| Sales Growth (QoQ) | 24.6% | -- |
| OP Growth (YoY) | -- | -- |
| OP Growth (QoQ) | -- | -- |
| Profit Growth (YoY) | -- | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (QoQ) | 103.0% | -- |
| OP Margin | 24.9% | 19.0% |
| Net Margin | 15.9% | 9.8% |
| Material Cost % | 33.9% | 38.2% |
| Employee Cost % | 21.6% | 24.0% |
| P/S | 1.20 | -- |
| P/E | 6.52 | -- |
| P/B | 2.62 | -- |
Exchange Filings
16Notice published by way of an advertisement in respect of 22nd Annual General Meeting (AGM) of the Company.
Submission of Annual Report of Goldline Pharmaceutical Limited for FY 2025-26.
Intimation of Book Closure
Intimation of Record Date for remote e-voting
Intimation of notice of 22nd AGM of Goldline Pharmaceutical Limited.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrikrishna Karkare
Appointment of M/s. Avinash Prakash Gandhewar, Practicing Company Secretaries, Membership No. FCS 11197 as Secretarial Auditor of the Company for the FY 2025-26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Disclosure under regulation 29 (2) of SEBI (SAST) Regulations, 2011
Outcome of Board Meeting held today, i.e., 09th June, 2026 for approval of financial results for the half year and year ended 31st march, 2026.
Intimation of Appointment of M/s. Kunal Dutt & Associates, Practicing Company Secretaries, Membership No. FCS 8831 as Internal Auditor of the Company.
Outcome of Board Meeting held today, i.e. 09th June, 2026 for approval of financials results for the half year and year ended 31st March, 2026.
Goldline Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/06/2026 ,inter alia, to consider and approve Standalone Audited ....
Intimation of Closure of Trading Window